Next Generation Sequencing Unit and Division of Virology, Faculty of Health Sciences, University of the Free State, Bloemfontein 9300, South Africa.
Department of Pediatrics, Kigali University Teaching Hospital, College of Medicine and Health Sciences, University of Rwanda, Kigali P.O. Box 4285, Rwanda.
Viruses. 2023 Nov 25;15(12):2321. doi: 10.3390/v15122321.
Although the introduction of rotavirus vaccines has substantially contributed to the reduction in rotavirus morbidity and mortality, concerns persist about the re-emergence of variant strains that might alter vaccine effectiveness in the long term. The G9 strains re-emerged in Africa during the mid-1990s and have more recently become predominant in some countries, such as Ghana and Zambia. In Rwanda, during the 2011 to 2015 routine surveillance period, G9P[8] persisted during both the pre- and post-vaccine periods. The pre-vaccination cohort was based on the surveillance period of 2011 to 2012, and the post-vaccination cohort was based on the period of 2013 to 2015, excluding 2014. The RotaTeq vaccine that was first introduced in Rwanda in 2012 is genotypically heterologous to Viral Protein 7 (VP7) G9. This study elucidated the whole genome of Rwandan G9P[8] rotavirus strains pre- and post-RotaTeq vaccine introduction. Fecal samples from Rwandan children under the age of five years (pre-vaccine n = 23; post-vaccine n = 7), conventionally genotyped and identified as G9P[8], were included. Whole-genome sequencing was then performed using the Illumina MiSeq platform. Phylogenetic analysis and pair-wise sequence analysis were performed using MEGA6 software. Distinct clustering of three post-vaccination study strains was observed in all 11 gene segments, compared to the other Rwandan G9P[8] study strains. Specific amino acid differences were identified across the gene segments of these three 2015 post-vaccine strains. Important amino acid differences were identified at position N242S in the VP7 genome segment of the three post-vaccine G9 strains compared to the other G9 strains. This substitution occurs at a neutralization epitope site and may slightly affect protein interaction at that position. These findings indicate that the Rwandan G9P[8] strains revealed a distinct sub-clustering pattern among post-vaccination study strains circulating in Rwanda, with changes at neutralization epitopes, which may play a role in neutralization escape from vaccine candidates. This emphasizes the need for continuous whole-genome surveillance to better understand the evolution and epidemiology of the G9P[8] strains post-vaccination.
虽然轮状病毒疫苗的引入大大降低了轮状病毒的发病率和死亡率,但人们仍然担心变异株的再次出现可能会长期影响疫苗的效果。G9 株于 20 世纪 90 年代中期在非洲再次出现,最近在加纳和赞比亚等一些国家成为主要流行株。在卢旺达,2011 年至 2015 年常规监测期间,G9P[8]在疫苗接种前和疫苗接种后均持续存在。疫苗接种前队列基于 2011 年至 2012 年的监测期,疫苗接种后队列基于 2013 年至 2015 年的监测期(不包括 2014 年)。2012 年首次在卢旺达引入的 RotaTeq 疫苗在病毒蛋白 7(VP7)G9 上具有基因异源性。本研究阐明了卢旺达 G9P[8]轮状病毒株在引入 RotaTeq 疫苗前后的全基因组。将年龄在 5 岁以下的卢旺达儿童的粪便样本(疫苗接种前 n=23;疫苗接种后 n=7)进行常规基因分型和鉴定为 G9P[8],然后使用 Illumina MiSeq 平台进行全基因组测序。使用 MEGA6 软件进行系统发育分析和序列比对分析。与其他卢旺达 G9P[8]研究株相比,三种疫苗接种后研究株在所有 11 个基因片段中均表现出明显的聚类。在这三种 2015 年疫苗接种后菌株的基因片段中发现了特定的氨基酸差异。在三种疫苗接种后 G9 株的 VP7 基因组片段中发现了位置 N242S 的重要氨基酸差异,与其他 G9 株相比。该取代发生在中和表位位点,可能会略微影响该位置的蛋白质相互作用。这些发现表明,在卢旺达 G9P[8]株中,疫苗接种后研究株之间存在明显的亚聚类模式,中和表位发生变化,这可能在疫苗候选物的中和逃逸中起作用。这强调了需要进行连续的全基因组监测,以更好地了解 G9P[8]株疫苗接种后的进化和流行病学。